Status:
COMPLETED
The Prediction Biomarkers of Survival Outcome for Severe Immune-related Hepatitis
Lead Sponsor:
Hunan Province Tumor Hospital
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Immune checkpoint inhibitors have revolutionized lung cancer (LC) treatment, demonstrating a significant improvement in overall survival. However high-grade immune-related adverse events (irAEs) may r...
Eligibility Criteria
Inclusion
- The lung cancers were diagnosed by pathological evaluation.
- The PD-1/PD-L1 inhibitors were administered in all patients.
- Grade 3-5 immune-related hepatitis had occurred.
- The pre-treatment tissues or peripheral blood were available.
Exclusion
- The pathological type was not lung cancers.
- Grade 1-2 immune-related hepatitis would be excluded.
- The any-grade hepatitis were induced by chemotherapy or virus.
Key Trial Info
Start Date :
May 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05326906
Start Date
May 1 2018
End Date
May 1 2022
Last Update
May 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hunan Cancer hospital
Changsha, Hunan, China